Skip to Content
Merck
  • Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures.

Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures.

Cell (2020-09-06)
Jacob M Wozniak, Robert H Mills, Joshua Olson, J R Caldera, Gregory D Sepich-Poore, Marvic Carrillo-Terrazas, Chih-Ming Tsai, Fernando Vargas, Rob Knight, Pieter C Dorrestein, George Y Liu, Victor Nizet, George Sakoulas, Warren Rose, David J Gonzalez
ABSTRACT

Staphylococcus aureus bacteremia (SaB) causes significant disease in humans, carrying mortality rates of ∼25%. The ability to rapidly predict SaB patient responses and guide personalized treatment regimens could reduce mortality. Here, we present a resource of SaB prognostic biomarkers. Integrating proteomic and metabolomic techniques enabled the identification of >10,000 features from >200 serum samples collected upon clinical presentation. We interrogated the complexity of serum using multiple computational strategies, which provided a comprehensive view of the early host response to infection. Our biomarkers exceed the predictive capabilities of those previously reported, particularly when used in combination. Last, we validated the biological contribution of mortality-associated pathways using a murine model of SaB. Our findings represent a starting point for the development of a prognostic test for identifying high-risk patients at a time early enough to trigger intensive monitoring and interventions.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Human FETUB / Fetuin-B ELISA Kit, for serum, plasma, cell culture supernatants and urine
Sigma-Aldrich
Hydroxylamine solution, 50 wt. % in H2O, 99.999%
Sigma-Aldrich
Acetonitrile, anhydrous, 99.8%